PTC Therapeutics, Inc.
PTCT
$73.46
-$1.56-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -131.39% | 287.90% | 265.87% | 231.21% | 202.70% |
| Total Depreciation and Amortization | 71.00% | -48.70% | -78.16% | -86.33% | -88.97% |
| Total Amortization of Deferred Charges | 2.00% | 1.75% | 1.93% | -17.43% | -30.62% |
| Total Other Non-Cash Items | -44.34% | -47.33% | -74.14% | -67.03% | -69.69% |
| Change in Net Operating Assets | -1,669.60% | -152.18% | -480.60% | 40.35% | -130.05% |
| Cash from Operations | -131.51% | 760.42% | 502.01% | 710.20% | 1,289.10% |
| Capital Expenditure | -711.82% | -36.27% | -23.52% | 48.15% | 104.91% |
| Sale of Property, Plant, and Equipment | -100.00% | -99.75% | -99.75% | -99.69% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,294.06% | -3,870.52% | -83.03% | -17.35% | 76.70% |
| Cash from Investing | -2,955.38% | -2,050.98% | -97.60% | -25.08% | 90.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -8.12% | 99.47% | 100.00% | 100.00% |
| Issuance of Common Stock | 88.90% | 193.35% | 548.88% | 271.55% | 80.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 10.47% | 4.50% | -100.56% | -102.12% | -76.33% |
| Cash from Financing | 23.93% | 29.40% | -93.52% | -97.45% | -58.82% |
| Foreign Exchange rate Adjustments | 16,526.32% | 409.93% | -3.53% | 392.38% | -98.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.31% | 9.72% | -59.12% | -17.91% | 181.32% |